{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:08:00Z","timestamp":1740128880359,"version":"3.37.3"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We estimated the risk of death from coronavirus disease 2019 in vaccinated compared with unvaccinated patients. The risk of death was reduced 44% after 1 dose of the Pfizer-BioNTech BNT162b2 vaccine, 55% after 1 dose of the Oxford-Astrazeneca ChAdOx1 vaccine, and 69% after 2 doses of the BNT162b2 vaccine. This is above the protection provided against infection.<\/jats:p>","DOI":"10.1093\/cid\/ciab881","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T23:34:56Z","timestamp":1695857696000},"page":"349-351","source":"Crossref","is-referenced-by-count":0,"title":["Effects of BNT162b2 Messenger RNA Vaccine and ChAdOx1 Adenovirus Vector Vaccine on Deaths From COVID-19 in Adults Aged \u226570 Years"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1301-5653","authenticated-orcid":false,"given":"Jamie","family":"Lopez Bernal","sequence":"first","affiliation":[{"name":"Public Health England , London , United Kingdom"},{"name":"NIHR Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine , London , United Kingdom"},{"name":"NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London , London , United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Andrews","sequence":"additional","affiliation":[{"name":"Public Health England , London , United Kingdom"},{"name":"NIHR Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine , London , United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Gower","sequence":"additional","affiliation":[{"name":"Public Health England , London , United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Stowe","sequence":"additional","affiliation":[{"name":"Public Health England , London , United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise","family":"Tessier","sequence":"additional","affiliation":[{"name":"Public Health England , London , United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Simmons","sequence":"additional","affiliation":[{"name":"Public Health England , London , United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Ramsay","sequence":"additional","affiliation":[{"name":"Public Health England , London , United Kingdom"},{"name":"NIHR Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine , London , United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"key":"2024021719314247300_CIT0001","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/S0140-6736(21)00790-X","article-title":"COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study.","volume":"397","author":"Hall","year":"2021","journal-title":"Lancet"},{"key":"2024021719314247300_CIT0002","doi-asserted-by":"crossref","first-page":"n1088","DOI":"10.1136\/bmj.n1088","article-title":"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.","volume":"373","author":"Lopez Bernal","year":"2021","journal-title":"BMJ"},{"key":"2024021719314247300_CIT0003","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(21)00289-9","article-title":"Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.","author":"Shrotri","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2024021719314247300_CIT0004","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting.","volume":"384","author":"Dagan","year":"2021","journal-title":"N Engl J Med"},{"key":"2024021719314247300_CIT0005","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"2024021719314247300_CIT0006","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine.","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"volume-title":"Technical summary: Public Health England data series on deaths in people with COVID-19 2020","author":"Public Health England.","key":"2024021719314247300_CIT0007"},{"volume-title":"COVID-19\u2014high risk shielded patient list identification methodology 2020","author":"NHS Digital.","key":"2024021719314247300_CIT0008"},{"volume-title":"Public Health England vaccine effectiveness report\u2014March 2021","year":"2021","author":"Public Health England.","key":"2024021719314247300_CIT0009"},{"key":"2024021719314247300_CIT0010","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","article-title":"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.","volume":"397","author":"Haas","year":"2021","journal-title":"Lancet"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciab881\/51779257\/ciab881.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/2\/349\/56697763\/ciab881.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/2\/349\/56697763\/ciab881.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T19:32:01Z","timestamp":1708198321000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/78\/2\/349\/7284079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":10,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,9,27]]},"published-print":{"date-parts":[[2024,2,17]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciab881","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"type":"print","value":"1058-4838"},{"type":"electronic","value":"1537-6591"}],"subject":[],"published-other":{"date-parts":[[2024,2,15]]},"published":{"date-parts":[[2023,9,27]]}}}